We use cookies to improve your experience on our site and to analyze traffic. By clicking "Accept", you consent to our use of cookies. Learn more.

Nova In Silico will be at ACoP 2026Meet the team and see our programDetails here

Model library

Disease and treatment models across major therapeutic areas, ready to simulate

Nova builds mechanistic QSP models in-house, and every Jinkō subscription includes a library of disease and treatment models imported from the literature to give you a head start.

18 Nova-built models · 53 literature models · 33 with a peer-reviewed source

Flagship models

Our most rigorously tested, published in-house models.

OncologyPeer-reviewed

NSCLC: EGFR-mutated

EGFR signaling, tumor growth, and acquired resistance

Prospective PFS prediction of the Phase III MARIPOSA trial matched the readout.

Peer-reviewed, npj Systems Biology and Applications, 2023
OncologyPublished

T-cell engager (TCE) platform

From bispecific binding to T-cell mediated tumor kill

Translational dose selection for T-cell-engaging bispecific antibodies.

Poster, ACOP 2023
OncologyPublished

Antibody-drug conjugate (ADC) platform

Antibody targeting, payload release, and tumor response

Payload delivery and tumor response modeling for ADC design.

Poster, ACOP 2024
CardiometabolicPeer-reviewed

Atherosclerotic cardiovascular disease (ASCVD)

From LDL-C and lipids to plaque and cardiovascular events

Prospective LDL-C prediction of the Phase III CORALreef trial matched the readout.

Peer-reviewed, npj Digital Medicine, 2025
Immunology & inflammationPeer-reviewed

Atopic dermatitis

Skin barrier breakdown and the immune cascade

Skin barrier and immune pathway biomarkers for trial design and stratification.

Peer-reviewed, Journal of Allergy and Clinical Immunology, 2024
Infectious diseasePublished

Influenza

Viral kinetics, immunization, and vaccine efficacy

Multi-strain vaccine efficacy across populations and age groups.

Poster, ASCPT 2023

Every model is accessed inside Jinkō. Here is how the two kinds differ.

Nova-built

Nova-built models

Mechanistic QSP models our scientists build in-house, including our published, peer-reviewed flagship models. Built for your program, and available in Jinkō.

Talk to our scientists
Imported from literature

Literature library

More than 100 disease and treatment models structured from published research, included with every Jinkō subscription. A fast starting point for building and simulating, with lighter curation than our in-house work.

Try Jinkō

Library explorer

Search 71 models across every therapeutic area

Filter by disease, target, model type, and evidence, then open any model in Jinkō.

Catalog updated 2026-08-18

Talk to our scientists

Showing 25 of 70 models

Sort:
ModelAreaSourceLicenseEvidence
Nonalcoholic steatohepatitis (NASH)
Nonalcoholic steatohepatitis (NASH), mechanistic model available on demand
Hepatology
Nova-built
Proprietary
Non Small Cell Lung Cancer
EGFR-mutated non-small cell lung carcinoma, mechanistic model available on demand
Oncology
Nova-built
Proprietary
Atopic Dermatitis
FLG-mutated atopic eczema, mechanistic model available on demand
Immunology & inflammation
Nova-built
Proprietary
Hepatitis B Virus (HBV)HBeAg-positiveHBeAg-negative
Hepatitis B virus infection, HBeAg-negative and HBeAg-positive, mechanistic model available on demand
Infectious disease
Nova-built
Proprietary
Influenza Vaccine
Influenza, mechanistic model available on demand
Infectious disease
Nova-built
Proprietary
Atherosclerotic Cardiovascular Disease (ASCVD)
Atherosclerotic cardiovascular disease, mechanistic model available on demand
Cardiometabolic
Nova-built
Proprietary
Acute Myeloid Leukemia (AML)
Acute myeloid leukemia, mechanistic model available on demand
Oncology
Nova-built
Proprietary
Prostate Cancer
Prostate Cancer, mechanistic model available on demand
Oncology
Nova-built
Proprietary
Nova - Gefitinib
Nova - Gefitinib - available on demand
Oncology
Nova-built
Proprietary
Antibody-drug conjugate (ADC) platform
Antibody-drug conjugate (ADC) platform, mechanistic model available on demand
Oncology
Nova-built
Proprietary
T-cell engager (TCE) platform
T-cell engager (TCE) platform, mechanistic model available on demand
Oncology
Nova-built
Proprietary
Nova - Cisplatin
Nova - Cisplatin - available on demand
Oncology
Nova-built
Proprietary
Nova - Osimertinib
Nova - Osimertinib - available on demand
Oncology
Nova-built
Proprietary
Nova - Entecavir
Nova - Entecavir - available on demand
Infectious disease
Nova-built
Proprietary
Nova - PegIfn2a
Nova - PegIfn2a - available on demand
Oncology
Nova-built
Proprietary
Nova - Venetoclax
Nova - Venetoclax - available on demand
Oncology
Nova-built
Proprietary
Nova - Ezetimibe
Nova - Ezetimibe - available on demand
Cardiometabolic
Nova-built
Proprietary
Hepatic glucose metabolism
Reusable building block: Hepatic glucose metabolism
Hepatology
Literature
CC BY 4.0
Pancreas model
Reusable building block: Pancreas model
Cardiometabolic
Literature
LGPL-3.0 (software)
Triple negative breast cancer
Disease and treatment model of triple-negative breast carcinoma
Oncology
Literature
CC BY 4.0
NSCLC
Disease and treatment model of non-small cell lung carcinoma
Oncology
Literature
CC BY 4.0
Triple Negative Breast Cancer - With Metastasis
Mechanistic QSP model of triple-negative breast carcinoma
Oncology
Literature
CC BY 4.0
Left ventricular hypertrophy
Mechanistic QSP model of left ventricular hypertrophy
Cardiometabolic
Literature
CC BY 4.0
HER2+ Breast cancer
Disease and treatment model of HER2 positive breast carcinoma
Oncology
Literature
CC BY 4.0
Covid-19
Disease and treatment model of COVID-19
Infectious disease
Literature
CC BY 4.0

This resource incorporates material from the referenced publication. Please review the applicable license and usage restrictions associated with that source. Your jinkō subscription does not grant additional rights to third-party material. Before use, ensure that your intended project complies with the applicable terms and obtain any additional permissions required, including for commercial use. Contact Nova In Silico for assistance with licensing enquiries.

Browse the full library in Jinkō

Two ways in, one platform.

Start simulating today. Get 53 literature models included with Jinkō.

Try Jinkō

Do not see your therapeutic area?

Our scientists build custom models, virtual populations, and Digital Twins, calibrated to your compound and your endpoints.

Request custom model